Background: Remote ischemic preconditioning (RIPC) of the limb has been shown to induce ischemic tolerance in basic and clinical studies that focused on sustained large artery occlusion rather than small vessel disease (SVD). This study aimed to evaluate the protective effects of brief repetitive limb RIPC on patients with cerebral SVD. Methods: Seventeen patients with cerebral SVD were enrolled. Patients underwent 5 ischemia-reperfusion cycles of preconditioning/sham preconditioning on both upper limbs twice a day for 1 year. Cerebral hemodynamic indexes, brain lesions, cognitive functions and assessment outcomes of dizziness handicap inventory (DHI) were analyzed. Results: In the RIPC group, the mean flow velocity (MFV) of the left middle cerebral artery (MCA) was accelerated (57.33 (52.33-61.34) vs. 51.33 (48.83-58.33), respectively; p = 0.038), and the post-treatment DHI score was reduced (18 (13-19) vs. 34 (21-45), respectively; p = 0.043). The post-treatment volume of the white matter lesions (WMLs) was also reduced (4.19 (2.96-7.25) vs. 6.06 (4.67-10.95), respectively; p = 0.050). There was no remarkable difference between the 2 groups either before or after treatment. Conclusion: The present study indicates that RIPC has potential beneficial effects on cerebral SVD by increasing the MFV of MCA, decreasing the DHI score as well as the volume of WMLs in patients with SVD.

Keywords:
Ischemic preconditioning, Small vessel disease, White matter lesions, Cognitive function, Dizziness
1.
Pantoni L: Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689-701.
2.
Wu B, Lin S, Hao Z, Yang J, Xu Y, Wu L, Zhang S, Liu M: Proportion, risk factors and outcome of lacunar infarction: a hospital-based study in a Chinese population. Cerebrovasc Dis 2010;29:181-187.
3.
Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia: Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/American stroke association. Stroke 2011;42:2672-2713.
4.
Weber R, Weimar C, Blatchford J, Hermansson K, Wanke I, Möller-Hartmann C, Gizewski ER, Forsting M, Demchuk AM, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A; PRoFESS Imaging Substudy Group: Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy. Stroke 2012;43:2336-2342.
5.
ten Dam VH, van den Heuvel DM, van Buchem MA, Westendorp RG, Bollen EL, Ford I, de Craen AJ, Blauw GJ; PROSPER Study Group: Effect of pravastatin on cerebral infarcts and white matter lesions. Neurology 2005;64:1807-1809.
6.
SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA: Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817-825.
7.
Cocho D, Belvís R, Martí-Fàbregas J, Bravo Y, Aleu A, Pagonabarraga J, Molina-Porcel L, Díaz-Manera J, San Roman L, Martínez-Lage M, Martínez A, Moreno M, Martí-Vilalta JL: Does thrombolysis benefit patients with lacunar syndrome? Eur Neurol 2006;55:70-73.
8.
Vlasov TD, Korzhevskiĭ DE, Poliakova EA: [Ischemic adaptation of the rat brain as a method for protection of endothelium from ischemic reperfusion injury]. Ross Fiziol Zh Im I M Sechenova 2004;90:40-48.
9.
Vlasov TD, Korzhevskii DE, Polyakova EA: Ischemic preconditioning of the rat brain as a method of endothelial protection from ischemic/repercussion injury. Neurosci Behav Physiol 2005;35:567-572.
10.
Rehni AK, Shri R, Singh M: Remote ischaemic preconditioning and prevention of cerebral injury. Indian J Exp Biol 2007;45:247-252.
11.
Ren C, Gao X, Steinberg GK, Zhao H: Limb remote-preconditioning protects against focal ischemia in rats and contradicts the dogma of therapeutic time windows for preconditioning. Neuroscience 2008;151:1099-1103.
12.
Hahn CD, Manlhiot C, Schmidt MR, Nielsen TT, Redington AN: Remote ischemic per-conditioning: a novel therapy for acute stroke? Stroke 2011;42:2960-2962.
13.
Meng R, Asmaro K, Meng L, Liu Y, Ma C, Xi C, Li G, Ren C, Luo Y, Ling F, Jia J, Hua Y, Wang X, Ding Y, Lo EH, Ji X: Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology 2012;79:1853-1861.
14.
Jacobson GP, Newman CW: The development of the dizziness handicap inventory. Arch Otolaryngol Head Neck Surg 1990;116:424-427.
15.
Koch S, Katsnelson M, Dong C, Perez-Pinzon M: Remote ischemic limb preconditioning after subarachnoid hemorrhage: a phase Ib study of safety and feasibility. Stroke 2011;42:1387-1391.
16.
Li L, Luo W, Huang L, Zhang W, Gao Y, Jiang H, Zhang C, Long L, Chen S: Remote perconditioning reduces myocardial injury in adult valve replacement: a randomized controlled trial. J Surg Res 2010;164:e21-e26.
17.
Bøtker HE, Kharbanda R, Schmidt MR, Bøttcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sørensen HT, Redington AN, Nielsen TT: Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010;375:727-734.
18.
Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O'Brien JT, Barkhof F, Benavente OR, et al: Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822-838.
19.
Schmidt R, Scheltens P, Erkinjuntti T, Pantoni L, Markus HS, Wallin A, Barkhof F, Fazekas F: White matter lesion progression: a surrogate endpoint for trials in cerebral small-vessel disease. Neurology 2004;63:139-144.
20.
Cho AH, Kim HR, Kim W, Yang DW: White matter hyperintensity in ischemic stroke patients: it may regress over time. J Stroke 2015;17:60-66.
21.
Rodríguez García PL, Rodríguez García D: Diagnosis of vascular cognitive impairment and its main categories. Neurologia 2015;30:223-239.
22.
Pantoni L, Poggesi A, Inzitari D: The relation between white-matter lesions and cognition. Curr Opin Neurol 2007;20:390-397.
23.
Benjamin P, Zeestraten E, Lambert C, Ster IC, Williams OA, Lawrence AJ, Patel B, MacKinnon AD, Barrick TR, Markus HS: Progression of MRI markers in cerebral small vessel disease: sample size considerations for clinical trials. J Cereb Blood Flow Metab 2016;36:228-240.
24.
Tuladhar AM, van Norden AG, de Laat KF, Zwiers MP, van Dijk EJ, Norris DG, de Leeuw FE: White matter integrity in small vessel disease is related to cognition. Neuroimage Clin 2015;7:518-524.
25.
Roubec M, Kuliha M, Jonszta T, Procházka V, Fadrná T, Filip M, Kanovsky P, Langová K, Herzig R, Skoloudík D: Detection of intracranial arterial stenosis using transcranial color-coded duplex sonography, computed tomographic angiography, and digital subtraction angiography. J Ultrasound Med 2011;30:1069-1075.
26.
Zhou Y, Hua Y, Jia L, Wang L, Liu B, Duan C, Jiao L: Evaluation of interventional therapy for patients with intracranial vertebral artery stenosis by transcranial color-coded sonography. Ultrasound Med Biol 2016;42:44-50.
27.
Jia L, Hua Y, Li J, Duan C, Zhou Y, Jiao L: Optimal ultrasound criteria for defining the severity of vertebral artery in-stent restenosis. Ultrasound Med Biol 2015;41:775-780.
28.
Nedelmann M, Stolz E, Gerriets T, Baumgartner RW, Malferrari G, Seidel G, Kaps M: Consensus recommendations for transcranial color-coded duplex sonography for the assessment of intracranial arteries in clinical trials on acute stroke. Stroke 2009;40:3238-3244.
29.
Kidwell CS, el-Saden S, Livshits Z, Martin NA, Glenn TC, Saver JL: Transcranial Doppler pulsatility indices as a measure of diffuse small-vessel disease. J Neuroimaging 2001;11:229-235.
30.
Chamorro A, Pujol J, Saiz A, Vila N, Vilanova JC, Alday M, Blanc R: Periventricular white matter lucencies in patients with lacunar stroke. A marker of too high or too low blood pressure? Arch Neurol 1997;54:1284-1288.
31.
Legarth J, Thorup E: Characteristics of Doppler blood-velocity waveforms in a cardiovascular in vitro model. I. The model and the influence of pulse rate. Scand J Clin Lab Invest 1989;49:451-457.
32.
Mok V, Ding D, Fu J, Xiong Y, Chu WW, Wang D, Abrigo JM, Yang J, Wong A, Zhao Q, et al: Transcranial Doppler ultrasound for screening cerebral small vessel disease: a community study. Stroke 2012;43:2791-2793.
33.
Kim JT, Lee SH, Hur N, Jeong SK: Blood flow velocities of cerebral arteries in lacunar infarction and other ischemic strokes. J Neurol Sci 2011;308:57-61.
34.
Schmidt EA, Piechnik SK, Smielewski P, Raabe A, Matta BF, Czosnyka M: Symmetry of cerebral hemodynamic indices derived from bilateral transcranial Doppler. J Neuroimaging 2003;13:248-254.
35.
Rodríguez Hernández SA, Kroon AA, van Boxtel MP, Mess WH, Lodder J, Jolles J, de Leeuw PW: Is there a side predilection for cerebrovascular disease? Hypertension 2003;42:56-60.
36.
Chang CC, Chang WN, Huang CR, Liou CW, Lin TK, Lu CH: The relationship between isolated dizziness/vertigo and the risk factors of ischemic stroke: a case control study. Acta Neurol Taiwan 2011;20:101-106.
37.
Wu CC, Young YH: Association between leukoaraiosis and saccadic oscillation. Arch Otolaryngol Head Neck Surg 2007;133:245-249.
38.
Walsh SR, Nouraei SA, Tang TY, Sadat U, Carpenter RH, Gaunt ME: Remote ischemic preconditioning for cerebral and cardiac protection during carotid endarterectomy: results from a pilot randomized clinical trial. Vasc Endovascular Surg 2010;44:434-439.
39.
Gonzalez NR, Hamilton R, Bilgin-Freiert A, Dusick J, Vespa P, Hu X, Asgari S: Cerebral hemodynamic and metabolic effects of remote ischemic preconditioning in patients with subarachnoid hemorrhage. Acta Neurochir Suppl 2013;115:193-198.
40.
Hougaard KD, Hjort N, Zeidler D, Sørensen L, Nørgaard A, Hansen TM, von Weitzel-Mudersbach P, Simonsen CZ, Damgaard D, Gottrup H, et al: Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial. Stroke 2014;45:159-167.
41.
Loukogeorgakis SP, Panagiotidou AT, Broadhead MW, Donald A, Deanfield JE, MacAllister RJ: Remote ischemic preconditioning provides early and late protection against endothelial ischemia-reperfusion injury in humans: role of the autonomic nervous system. J Am Coll Cardiol 2005;46:450-456.
42.
Schoemaker RG, van Heijningen CL: Bradykinin mediates cardiac preconditioning at a distance. Am J Physiol Heart Circ Physiol 2000;278:H1571-H1576.
43.
Patel HH, Moore J, Hsu AK, Gross GJ: Cardioprotection at a distance: mesenteric artery occlusion protects the myocardium via an opioid sensitive mechanism. J Mol Cell Cardiol 2002;34:1317-1323.
44.
Thompson JW, Dave KR, Young JI, Perez-Pinzon MA: Ischemic preconditioning alters the epigenetic profile of the brain from ischemic intolerance to ischemic tolerance. Neurotherapeutics 2013;10:789-797.
45.
Sabbagh S, Henry Salzman MM, Kloner RA, Simkhovich BZ, Rezkalla SH: Remote ischemic preconditioning for coronary artery bypass graft operations. Ann Thorac Surg 2013;96:727-736.
46.
Liu XQ, Sheng R, Qin ZH: The neuroprotective mechanism of brain ischemic preconditioning. Acta Pharmacol Sin 2009;30:1071-1080.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.